STCube to Participate in September World Conference on Lung Cancer... "Presentation of Small Cell Lung Cancer Research Results"

STCube announced on the 25th that it will present advanced research results on the immune checkpoint inhibitor 'Nelmastobat' in a poster session at the '2023 World Conference on Lung Cancer.'

The World Conference on Lung Cancer is the largest academic conference specializing in lung cancer and other thoracic malignancies, marking its 24th edition this year. It is hosted by the International Association for the Study of Lung Cancer. This prestigious event attracts more than 7,000 experts from over 100 countries worldwide every year.

This year, the conference will be held in Singapore from September 9 to 12 (local time). The full abstract of the presentations will be released on the conference website on August 16.

At this conference, STCube plans to focus on presenting the expression characteristics of BTN1A1 (an immune checkpoint protein first discovered globally by STCube) in small cell lung cancer.

Small cell lung cancer accounts for approximately 10-15% of all lung cancer patients. Compared to non-small cell lung cancer, it has a faster tumor growth rate and tends to metastasize systemically, making chemotherapy and radiation therapy prioritized over surgery. Cases cured by first-line treatment alone are extremely rare, and the average survival rate in the early stages of cancer is less than two years.

An STCube representative stated, "In the case of small cell lung cancer, all three patients treated with Nelmastobat in phase 1 clinical trials have maintained progression-free survival to date," adding, "We believe it will be a very useful treatment when used in combination with chemotherapy or PD-L1 immune checkpoint inhibitors." They further added, "Along with entering phase 2, we are also conducting more detailed discussions on technology transfer with global pharmaceutical companies."

STCube is currently preparing to submit the phase 2 clinical trial application (IND) for Nelmastobat to the Korea Food and Drug Administration and the U.S. Food and Drug Administration (FDA), targeting small cell lung cancer as the indication. Having confirmed safety and efficacy in phase 1 clinical trials, STCube is preparing the phase 2 IND submission in collaboration with CROs (Contract Research Organizations) and CMOs (Contract Manufacturing Organizations).

This content was produced with the assistance of AI translation services.